Integer Holdings Co. (NASDAQ:ITGR) shares dropped 1.3% during mid-day trading on Thursday . The company traded as low as $22.83 and last traded at $23.05, with a volume of 355,212 shares trading hands. The stock had previously closed at $23.36.

ITGR has been the topic of a number of recent analyst reports. TheStreet cut Integer Holdings from a “hold” rating to a “sell” rating in a research report on Friday, July 1st. Zacks Investment Research upgraded Integer Holdings from a “sell” rating to a “hold” rating in a research report on Thursday, May 19th. Finally, Sterne Agee CRT reiterated a “buy” rating on shares of Integer Holdings in a research report on Monday, May 16th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $57.00.

The stock’s market cap is $721.98 million. The firm has a 50 day moving average of $0.00 and a 200-day moving average of $0.00.

Integer Holdings (NASDAQ:ITGR) last issued its quarterly earnings results on Thursday, July 28th. The company reported $0.56 EPS for the quarter, missing analysts’ consensus estimates of $0.70 by $0.14. The firm earned $348.38 million during the quarter, compared to analysts’ expectations of $356.72 million. During the same quarter in the previous year, the company earned $0.73 earnings per share. Integer Holdings’s revenue was up 99.2% on a year-over-year basis. On average, equities analysts anticipate that Integer Holdings Co. will post $2.64 EPS for the current year.

Greatbatch, Inc is a developer and manufacturer of medical devices and components. The Company operates through two segments: Greatbatch Medical and QiG Group (QiG). Greatbatch Medical designs and manufactures products where the Company either owns the intellectual property or has unique manufacturing and assembly expertise.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.